COSM
Cosmos Health Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$11M
5Y Perf.-96.3%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
COSM vs XTLB
Revenue, margins, valuation, and 5-year total return — side by side.
XTLB
XTL Biopharmaceuticals Ltd.
Biotechnology
Market Cap$294K
5Y Perf.-50.2%
COSM vs XTLB — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | COSM | XTLB |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
| Market Cap | $11M | $294K |
| Revenue (TTM) | $60M | $451K |
| Net Income (TTM) | $-19M | $-1M |
| Gross Margin | 11.4% | 26.4% |
| Operating Margin | -23.9% | -481.6% |
| Total Debt | $12M | $138K |
| Cash & Equiv. | $315K | $371K |
COSM vs XTLB — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
COSM
XTLB
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Cosmos Health Inc. (COSM) | 100 | 3.7 | -96.3% |
| XTL Biopharmaceutic… (XTLB) | 100 | 49.8 | -50.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: COSM vs XTLB
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: COSM leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. XTL Biopharmaceuticals Ltd. is the stronger pick specifically for capital preservation and lower volatility and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
COSM
Cosmos Health Inc.
The Growth Play
COSM carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 2.0%, EPS growth 45.6%, 3Y rev CAGR -1.1%
- 37.8% 10Y total return vs XTLB's -87.3%
- 2.0% revenue growth vs XTLB's -173.2%
Best for: growth exposure and long-term compounding
XTLB
XTL Biopharmaceuticals Ltd.
The Income Pick
XTLB is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 1.71
- Lower volatility, beta 1.71, Low D/E 2.5%, current ratio 0.61x
- Beta 1.71, current ratio 0.61x
Best for: income & stability and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | COSM | 2.0% revenue growth vs XTLB's -173.2% |
| Quality / Margins | COSM | -31.0% margin vs XTLB's -227.7% |
| Stability / Safety | XTLB | Beta 1.71 vs COSM's 1.72, lower leverage |
| Dividends | COSM | 92.4% yield; 1-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | COSM | -17.0% vs XTLB's -50.9% |
| Efficiency (ROA) | XTLB | -17.7% ROA vs COSM's -26.7%, ROIC -54.1% vs -28.9% |
COSM vs XTLB — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
Segment breakdown not available.
COSM vs XTLB — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCOSMLAGGINGXTLB
XTLBXTL Biopharmaceutical…
2leads
COSMCosmos Health Inc.
2leads
6 Total Categories
CATEGORYLEADERvs XTLBMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
COSM4/5
Valuation MetricsMultiples, price ratios, and targets
COSM2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
XTLB5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
XTLB4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
COSM leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
COSM is the larger business by revenue, generating $60M annually — 132.6x XTLB's $451,000. Profitability is closely matched — net margins range from -31.0% (COSM) to -2.3% (XTLB).
| Metric | COSMCosmos Health Inc. | XTLBXTL Biopharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | $60M | $451,000 |
| EBITDAEarnings before interest/tax | -$13M | -$1M |
| Net IncomeAfter-tax profit | -$19M | -$1M |
| Free Cash FlowCash after capex | -$10M | $0 |
| Gross MarginGross profit ÷ Revenue | +11.4% | +26.4% |
| Operating MarginEBIT ÷ Revenue | -23.9% | -4.8% |
| Net MarginNet income ÷ Revenue | -31.0% | -2.3% |
| FCF MarginFCF ÷ Revenue | -17.2% | -3.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +37.9% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +62.2% | +20.0% |
COSM leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
COSM leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | COSMCosmos Health Inc. | XTLBXTL Biopharmaceut… |
|---|---|---|
| Market CapShares × price | $11M | $293,767 |
| Enterprise ValueMkt cap + debt − cash | $23M | $60,767 |
| Trailing P/EPrice ÷ TTM EPS | -0.30x | -0.28x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.20x | 0.65x |
| Price / BookPrice ÷ Book value/share | 0.27x | 0.05x |
| Price / FCFMarket cap ÷ FCF | — | — |
COSM leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
XTLB leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
XTLB delivers a -25.5% return on equity — every $100 of shareholder capital generates $-26 in annual profit, vs $-80 for COSM. XTLB carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to COSM's 0.48x.
| Metric | COSMCosmos Health Inc. | XTLBXTL Biopharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | -80.1% | -25.5% |
| ROA (TTM)Return on assets | -26.7% | -17.7% |
| ROICReturn on invested capital | -28.9% | -54.1% |
| ROCEReturn on capital employed | -44.3% | -50.7% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 3 |
| Debt / EquityFinancial leverage | 0.48x | 0.03x |
| Net DebtTotal debt minus cash | $12M | -$233,000 |
| Cash & Equiv.Liquid assets | $315,105 | $371,000 |
| Total DebtShort + long-term debt | $12M | $138,000 |
| Interest CoverageEBIT ÷ Interest expense | -9.42x | -13.31x |
XTLB leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
XTLB leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in XTLB five years ago would be worth $1,963 today (with dividends reinvested), compared to $547 for COSM. Over the past 12 months, COSM leads with a -17.0% total return vs XTLB's -50.9%. The 3-year compound annual growth rate (CAGR) favors XTLB at -18.4% vs COSM's -52.8% — a key indicator of consistent wealth creation.
| Metric | COSMCosmos Health Inc. | XTLBXTL Biopharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | -32.0% | +11.3% |
| 1-Year ReturnPast 12 months | -17.0% | -50.9% |
| 3-Year ReturnCumulative with dividends | -89.5% | -45.7% |
| 5-Year ReturnCumulative with dividends | -94.5% | -80.4% |
| 10-Year ReturnCumulative with dividends | +37.8% | -87.3% |
| CAGR (3Y)Annualised 3-year return | -52.8% | -18.4% |
XTLB leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — COSM and XTLB each lead in 1 of 2 comparable metrics.
Risk & Volatility
XTLB is the less volatile stock with a 1.71 beta — it tends to amplify market swings less than COSM's 1.72 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | COSMCosmos Health Inc. | XTLBXTL Biopharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.72x | 1.71x |
| 52-Week HighHighest price in past year | $1.32 | $10.28 |
| 52-Week LowLowest price in past year | $0.28 | $1.05 |
| % of 52W HighCurrent price vs 52-week peak | +26.5% | +26.0% |
| RSI (14)Momentum oscillator 0–100 | 48.6 | 57.0 |
| Avg Volume (50D)Average daily shares traded | 793K | 2.4M |
Evenly matched — COSM and XTLB each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
COSM is the only dividend payer here at 92.44% yield — a key consideration for income-focused portfolios.
| Metric | COSMCosmos Health Inc. | XTLBXTL Biopharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | +92.4% | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | $0.32 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
COSM leads in 2 of 6 categories (Income & Cash Flow, Valuation Metrics). XTLB leads in 2 (Profitability & Efficiency, Total Returns). 1 tied.
Best OverallCosmos Health Inc. (COSM)Leads 2 of 6 categories
Loading custom metrics...
COSM vs XTLB: Frequently Asked Questions
6 questions · data-driven answers · updated daily
01Which is the better long-term investment — COSM or XTLB?
Over the past 5 years, XTL Biopharmaceuticals Ltd.
(XTLB) delivered a total return of -80. 4%, compared to -94. 5% for Cosmos Health Inc. (COSM). Over 10 years, the gap is even starker: COSM returned +37. 8% versus XTLB's -87. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — COSM or XTLB?
By beta (market sensitivity over 5 years), XTL Biopharmaceuticals Ltd.
(XTLB) is the lower-risk stock at 1. 71β versus Cosmos Health Inc. 's 1. 72β — meaning COSM is approximately 1% more volatile than XTLB relative to the S&P 500. On balance sheet safety, XTL Biopharmaceuticals Ltd. (XTLB) carries a lower debt/equity ratio of 3% versus 48% for Cosmos Health Inc. — giving it more financial flexibility in a downturn.
03Which has better profit margins — COSM or XTLB?
Cosmos Health Inc.
(COSM) is the more profitable company, earning -29. 7% net margin versus -227. 7% for XTL Biopharmaceuticals Ltd. — meaning it keeps -29. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: COSM leads at -28. 6% versus -481. 6% for XTLB. At the gross margin level — before operating expenses — COSM leads at 7. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
04Which pays a better dividend — COSM or XTLB?
In this comparison, COSM (92.
4% yield) pays a dividend. XTLB does not pay a meaningful dividend and should not be held primarily for income.
05Is COSM or XTLB better for a retirement portfolio?
For long-horizon retirement investors, Cosmos Health Inc.
(COSM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (92. 4% yield). XTL Biopharmaceuticals Ltd. (XTLB) carries a higher beta of 1. 71 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (COSM: +37. 8%, XTLB: -87. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
06What are the main differences between COSM and XTLB?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: COSM is a small-cap income-oriented stock; XTLB is a small-cap quality compounder stock. COSM pays a dividend while XTLB does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.